Galecto Joins 2020's NASDAQ Gold Rush With $85m Launch

16 Biopharma IPOs In October

 
• By Andrew McConaghie

Denmark-headquartered company’s lead candidate is an inhaled therapy for idiopathic pulmonary fibrosis.

Galecto - Nasdaq
2020 is already a record-breaker in terms of the number of IPOs

More from Business

More from Scrip